We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Arrowhead Pharmaceuticals Inc (ARWR) Common Stock USD0.001

Sell:$32.08 Buy:$32.11 Change: $1.93 (5.68%)
Market closed |  Prices as at close on 29 February 2024 | Switch to live prices |
Change: $1.93 (5.68%)
Market closed |  Prices as at close on 29 February 2024 | Switch to live prices |
Change: $1.93 (5.68%)
Market closed |  Prices as at close on 29 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Contact details

177 E Colorado Blvd, Suite 700
United States
+1 (626) 6964702

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$3.86 billion
Shares in issue:
123.90 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Christopher Anzalone
    President, Chief Executive Officer, Director
  • Kenneth Myszkowski
    Chief Financial Officer
  • Patrick O'Brien
    Chief Operating Officer, General Counsel, Company Secretary
  • James Hamilton
    Chief of Discovery and Translational Medicine
  • Tracie Oliver
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.